Immunic (NASDAQ:IMUX - Get Free Report) is expected to be issuing its Q1 2025 quarterly earnings data before the market opens on Wednesday, May 14th. Analysts expect the company to announce earnings of ($0.26) per share for the quarter.
Immunic Price Performance
Shares of NASDAQ:IMUX opened at $1.07 on Wednesday. The business has a 50-day moving average of $1.08 and a two-hundred day moving average of $1.10. Immunic has a fifty-two week low of $0.83 and a fifty-two week high of $2.11. The stock has a market capitalization of $102.05 million, a P/E ratio of -0.87 and a beta of 1.73.
Wall Street Analysts Forecast Growth
A number of analysts have recently weighed in on IMUX shares. William Blair began coverage on shares of Immunic in a research note on Tuesday, March 25th. They issued an "outperform" rating for the company. D. Boral Capital reaffirmed a "buy" rating and set a $17.00 target price on shares of Immunic in a research report on Wednesday, April 30th. HC Wainwright restated a "buy" rating and issued a $10.00 price target on shares of Immunic in a research report on Thursday, May 1st. B. Riley reaffirmed a "buy" rating and set a $6.00 price objective on shares of Immunic in a research report on Wednesday, April 16th. Finally, StockNews.com downgraded Immunic from a "hold" rating to a "sell" rating in a research report on Thursday, March 20th. One research analyst has rated the stock with a sell rating, six have assigned a buy rating and two have given a strong buy rating to the company's stock. According to data from MarketBeat.com, Immunic presently has a consensus rating of "Buy" and a consensus price target of $13.20.
Read Our Latest Analysis on IMUX
Immunic Company Profile
(
Get Free Report)
Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Immunic, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Immunic wasn't on the list.
While Immunic currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
